Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study

Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be validated. We prospectively recruited 184 resectable...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Rui, Huang, Jun, Tian, Xiaoru, Liang, Chaoyang, Xiong, Yuanyuan, Zhang, Jia‐Tao, Jiang, Benyuan, Dong, Song, Gong, Yuhua, Gao, Wei, Li, Fang, Shi, Yonglei, Liu, Zhentian, Gao, Xuan, Chen, Rongrong, Zhong, Wenzhao, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158775/
https://www.ncbi.nlm.nih.gov/pubmed/36732646
http://dx.doi.org/10.1002/1878-0261.13387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158775/
https://www.ncbi.nlm.nih.gov/pubmed/36732646
http://dx.doi.org/10.1002/1878-0261.13387

Ejemplares similares